Skip to main content
    O

    Oculis Holding AG Ordinary shares (OCS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.40
    +0.23 (+3.21%)

    Market Cap: $441.59M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    21%(3/14)
    Avg Surprise
    -39.37%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.40
    Range$-0.48 - $-0.30
    8 analysts
    EPS RevisionsNo revisions (7d)
    2
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.42+4.4%
    60d ago$-0.40-0.8%
    30d ago$-0.400.0%
    7d ago$-0.400.0%
    Current$-0.40
    Revenue Consensus
    $157590
    Range$0 - $300000
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.38
    Range$-0.51 - $-0.23
    7 analysts
    Revenue Consensus
    $407000
    Range$28950 - $727950
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.38---
    Sep 26EST
    		-$-0.40---
    Jun 26
    Reported Aug 6
    		$-0.20N/A+58.33%Beat+59.2%
    Mar 26
    Reported May 11
    		$-0.49$-0.41-19.51%Miss+29.0%
    Dec 25
    Reported Mar 3
    		$-0.42$-0.41-2.14%Miss+37.3%
    Sep 25
    Reported Nov 10
    		$-0.32$-0.41+21.95%Beat+33.3%
    Jun 25
    Reported Aug 21
    		$-0.49$-0.45-8.89%Miss+3.9%
    Mar 25
    Reported May 8
    		$-0.69$-0.40-72.50%Miss-56.8%
    Dec 24
    Reported Mar 11
    		$-0.67$-0.43-55.81%Miss-97.1%
    Sep 24
    Reported Nov 7
    		$-0.48$-0.42-14.29%Miss-41.2%
    Jun 24
    Reported Aug 27
    		$-0.51$-0.37-36.58%Miss-34.2%
    Mar 24
    Reported May 8
    		$-0.44$-0.40-10.00%Miss+70.9%
    Dec 23
    Reported Mar 18
    		$-0.34$-0.39+12.82%Beat-466.7%
    Sep 23
    Reported Nov 15
    		$-0.34$-0.25-36.00%Miss-1600.0%
    Jun 23
    Reported Aug 29
    		$-0.38$-0.29-31.03%Miss-3900.0%
    Mar 23
    Reported Mar 31
    		$-1.51$-0.33-357.58%Miss-1472.7%
    Dec 22
    Reported Mar 28
    		$-0.06N/AN/ABeat-100.0%
    Sep 22
    Reported Nov 14
    		$-0.02$0.00N/AMiss-128.6%
    Jun 22
    Reported Aug 15
    		$0.01$0.00N/ABeat-75.0%
    Mar 22
    Reported May 16
    		$0.11$0.00N/ABeat+450.0%
    Dec 21
    Reported Mar 30
    		$-0.03$0.00N/AMiss-
    Sep 21
    Reported Nov 23
    		$0.07$0.00N/ABeat-
    Jun 21
    Reported Aug 18
    		$0.04$0.00N/ABeat-
    Mar 21
    Reported Jun 22
    		$0.02$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.13EV/EBITDAN/A
    Price/FCF-5.49xFCF Yield-18.22%
    Profitability
    Profit Margin0.00%Operating Margin-7603.00%
    ROE-43.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-85.39x
    Current Ratio8.35xQuick Ratio8.35x
    Trading Statistics
    Beta0.27Avg Volume328.08K
    52-Week High$34.4852-Week Low$7.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.16
    SMA 20$8.88
    SMA 50$10.87
    SMA 200$19.57
    EMA 10$8.09
    EMA 20$8.81
    EMA 50$10.49
    EMA 200$16.22

    MACD

    Line: -0.94Signal: -0.87Hist: -0.07

    ADX

    ADX: 40.3+DI: 8.0-DI: 33.4

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$8.51

    Bollinger Bands

    Upper Band$10.76
    Lower Band$6.99
    %B Position4243%(Upper)
    Band Width0.11

    RSI (14-Day)

    Oversold
    24.1

    Momentum Oscillators

    Stoch %K8.7
    Stoch %D6.1
    Williams %R-87.8
    ROC (10d)-15.5%
    Momentum-1.36
    CCI (20d)-141.0
    MFI (14d)39.8

    Volatility Measures

    ATR (14d)$0.52(7.0%)
    StdDev (20d)0.94
    Hist Vol56.6%(High)

    Volume Flow

    VWAP$7.38
    OBV-5.0M
    AD Line-8.1M
    CMF (20d)-0.169

    Volume Metrics

    Avg Vol (20d)332.8K
    Vol Ratio1.7x(High)
    VWMA (20d)$8.72

    Pivot Points

    R3$8.20
    R2$7.97
    R1$7.57
    Pivot Point$7.34
    S1$6.94
    S2$6.71
    S3$6.31

    Advanced Oscillators

    TSI-51.26
    Ultimate Osc33.5
    KST-267.65

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$243,000$261,000$0$0$0$245,000$222,000$185,000$219,000
    Cost of RevenueN/A$157,434N/AN/A$14.91MN/AN/AN/A$16.46M$10.86M$8.03M$8.87M
    Gross ProfitN/A$-157,434N/A$243,000$-14,648,000N/AN/AN/A$-16,220,000$-10,634,000$-7,844,000$-8,653,000
    Operating Expenses$23.57M$22.27M$20.88M$20.54M$6.12M$19.97M$17.26M$18.13M$22.48M$15.33M$12.18M$12.96M
    R&D$15.28M$14.27M$13.19M$14.12M$14.91M$14.77M$11.76M$13.00M$16.46M$10.86M$8.03M$8.87M
    SG&A$7.55M$7.18M$6.90M$6.42M$5.43M$4.92M$5.00M$4.66M$5.21M$4.05M$4.10M$3.65M
    Operating Income$-23,568,000$-22,426,315$-20,884,092$-20,296,000$-20,768,000$-19,974,000$-17,260,000$-18,131,000$-22,485,000$-15,328,000$-12,184,000$-12,959,000
    Interest Income$592,000$367,000$319,000$438,000$520,000$493,000$371,000$556,000$660,000$581,000$656,000$520,000
    Interest Expense$309,000$176,858$239,168$202,428$183,000$247,000$246,000$264,000$87,000$41,000$12,000$11,000
    Income Before Tax$-9,964,000$-29,595,744$-23,515,940$-16,842,000$-25,399,000$-33,206,000$-28,893,000$-20,172,000$-20,809,000$-16,063,000$-12,512,000$-17,529,000
    Income Tax Expense$6,000$-100,185$-180,616$13,000$-24,000$7,000$-238,000$18,000$30,000$30,000$-13,000$-116,000
    Net Income$-9,970,000$-29,495,558$-23,335,323$-16,855,000$-25,375,000$-33,213,000$-28,655,000$-20,190,000$-20,839,000$-16,093,000$-12,499,000$-17,413,000
    EBITDA$-9,477,000$-29,261,452$-23,118,772$-16,487,572$-25,103,000$-32,836,000$-28,525,000$-19,786,000$-20,633,000$-15,949,000$-12,426,000$-17,445,000
    EBIT$-9,655,000$-29,418,886$-23,276,772$-16,639,572$-25,216,000$-32,959,000$-28,647,000$-19,908,000$-20,722,000$-16,022,000$-12,500,000$-17,518,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OCS

    News

    (OCS) Risk Channels and Responsive Allocation

    This article analyzes Oculis Holding Ag (NYSE: OCS), indicating weak sentiment across all time horizons supporting a short bias. It highlights a mid-channel oscillation pattern and an exceptional 314.0:1 risk-reward...

    Stock Traders Daily•10/15/26•Bearish

    Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

    Oculis Holding AG has published a notification regarding transactions by persons discharging managerial responsibilities. The notification concerns the vesting and settlement of Restricted Stock Units (RSUs) previously...

    GlobeNewswire•10/8/26•Neutral

    Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

    Oculis Holding AG announced the publication of notifications regarding transactions by persons discharging managerial responsibilities. These notifications relate to the vesting and settlement of Restricted Stock Units...

    Yahoo Finance•10/8/26•Neutral

    Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

    Oculis Holding AG announced that its CEO, Riad Sherif, M.D., will present Licaminlimab at Eyecelerator @ AAO 2026...

    GlobeNewswire•10/7/26•Bullish

    Oculis to Present Licaminlimab Precision Medicine Approach for Dry Eye Disease at AAO 2026, PREDICT-1 Topline Readout Expected by Year-End

    Oculis Holding AG announced that its CEO, Dr. Riad Sherif, will present Licaminlimab, a novel topical anti-TNFα candidate for TNFR1-mediated dry eye disease, at AAO 2026...

    Quiver Quantitative•10/7/26•Bullish

    OCS Valuation and Fair Value

    P/E
    -4.1x
    P/FCF
    -5.5x
    P/B
    1.7x
    See GNG's fair value

    OCS Profitability: Margins, ROIC and FCF

    Operating margin
    -7603.0%
    Net margin
    0.0%
    ROE
    -43.7%
    FCF yield
    -18.2%

    OCS Competitors

    CompanyTicker
    KamadaKMDA
    Alpha Teknova IncTKNO
    Neurogene IncNGNE
    XOMA CorporationXOMAO
    Cerus CorporationCERS
    XOMA Royalty CorporationXOMAP
    National Research CorpNRC
    Entera Bio LtdENTX

    Sector: Healthcare

    OCS Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    3
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    OCS Bull Case vs Bear Case

    Bull case

    • OCS grew quarterly revenue 18.8% year over year.
    • 100.0% of OCS's analyst ratings are Buy or Strong Buy.

    Bear case

    • OCS beat EPS estimates in 25.0% of its last 8 reported quarters.

    OCS Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -11.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.40
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 2 down

    Frequently Asked Questions About OCS

    Does OCS pay dividends?

    Oculis Holding AG Ordinary shares (OCS) does not currently pay a regular dividend.

    What is OCS's market cap?

    Oculis Holding AG Ordinary shares (OCS) has a market capitalization of $441.59M with a current stock price of $7.40.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In